JAMP-TOPIRAMATE TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

TOPIRAMATE

Mevcut itibaren:

JAMP PHARMA CORPORATION

ATC kodu:

N03AX11

INN (International Adı):

TOPIRAMATE

Doz:

100MG

Farmasötik formu:

TABLET

Kompozisyon:

TOPIRAMATE 100MG

Uygulama yolu:

ORAL

Paketteki üniteler:

30/100/500

Reçete türü:

Prescription

Terapötik alanı:

MISCELLANEOUS ANTICONVULSANTS

Ürün özeti:

Active ingredient group (AIG) number: 0132938002; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2015-01-06

Ürün özellikleri

_JAMP-Topiramate (Topiramate Tablets) Page 1 of 79_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION PR
JAMP-TOPIRAMATE
Topiramate Tablets
Tablets, 25 mg, 100 mg and 200 mg, oral
USP
Antiepileptic/Migraine Prophylaxis
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
JAN 06, 2015
Date of Revision:
APR 20, 2023
Submission Control Number: 273323
_ _
_ _
_ _
_JAMP-Topiramate (Topiramate Tablets) Page 2 of 79 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Serious Skin
Reactions
04/2023
7 WARNINGS AND PRECAUTIONS, Metabolic Acidosis
04/2023
7 WARNINGS AND PRECAUTIONS, Ophthalmologic
04/2023
TABLE OF CONTENTS
_Sections or subsections that are not applicable at the time of
authorization are not listed. _
RECENT MAJOR LABEL CHANGES
......................................................................................
2
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS...............................................................................................................
4
1.1
Pediatrics
.........................................................................................................
4
1.2
Geriatrics
..........................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
4
DOSAGE AND ADMINISTRATION
..............................................................................
5
4.1
Dosing Considerations
.....................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................. 5
4.4
Administration
.......................................................................................